#Oncomastodon @JAMASurgery #Clinicalinvestigation Axillary staging based on targeted axillary dissection (TAD) without axillary lymph node dissection (ALND) after neoadjuvant systemic therapy (NST) in patients with node-positive #breastcancer cancer was associated with excellent clinical outcomes in selected patients, mainly those with good response to NST and at least 3 TAD lymph nodes.

#molecularapproach #Oncomastodon Recap : understanding of cancer as a genetic disease .Cancer cells acquire their characteristics at different times during cancer development, in diverse microenvironments, via various mechanisms .It is increasingly clear that the phenotypic variations underlying cancer result from multiple interactions among numerous environmental & genetic factors that occur over long period
https://academic.oup.com/carcin/issue/36/Suppl_1

#oncologyresearch #Oncomastodon #Immunology @Nature
Expanding the understanding of site-specific antimetastatic #immunity. Locally sourced: site-specific immune barriers to #metastasis
📌 https://www.nature.com/articles/s41577-023-00836-2
📌 https://www.nature.com/nri/

#Oncomastodon #cancerresearch The first GWAS on mammographic texture variation in ~7000 women. This #Clinicalstudy identified novel texture variation loci and shared loci between texture variation, mammographic density, and #breastcancer risk
📌https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-022-01570-8 @_YuxiLiu @bmc
📌https://breast-cancer-research.biomedcentral.com

#Oncomastodon In high-risk #Hodgkinslymphoma, brentuximab vedotin in combination with #chemotherapy has shown greater efficacy than chemotherapy alone, but at the cost of increased toxic effects.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2206660?articleTools=true
https://www.nejm.org/do/10.1056/NEJMdo006741/full/
@NEJM